Enveric Biosciences Announces Positive Results from Recently Completed IND-enabling ADMET StudiesBusiness Wire · 3 days ago
Enveric Biosciences Secures New U.S. Patent Allowance for Next-Generation, Non-Hallucinogenic Mescaline Derivatives in EVM401 SeriesBusiness Wire · Sep 15, 2026
Enveric Biosciences to Present at H.C. Wainwright 28th Annual Global Investment ConferenceBusiness Wire · Sep 1, 2026
Enveric Biosciences Reports Financial Results and Provides Corporate Update for Second Quarter 2026Business Wire · Aug 14, 2026
Enveric Biosciences Says New Preclinical Data Confirms Non-Hallucinogenic Profile For Lead Psychiatric CandidateBenzinga · Aug 5, 2026
Enveric Biosciences Reports New Preclinical Data Supporting the Non-Hallucinogenic Profile of Lead Candidate EB-003Business Wire · Aug 5, 2026Enveric Biosciences, Inc. is a pharmaceutical firm focused on advancing diverse cannabinoid-based medications, primarily for use in cancer care. The company's robust product pipeline includes EV104, developed for treating osteoarthritis, and EVM-101 and EVM-201, which are intended to alleviate cancer-related distress. Furthermore, EVM-301 is under development for a mental health indication, alongside EV102, a cannabinoid cream formulated for topical skin application.
| Date | Est. | Actual | |
|---|---|---|---|
| Aug 14, 2026 | – | -$0.76 | |
| May 15, 2026 | – | -$1.08 | |
| Mar 27, 2026 | -$55.80 | $0.85 | Beat |
| Nov 14, 2025 | -$63.00 | -$10.81 | Beat |
| Aug 11, 2025 | -$63.00 | -$11.64 | Beat |
| May 13, 2025 | -$72.00 | -$14.64 | Beat |